Trimmed means for symptom trials with dropouts

Pharmaceutical Statistics

Volumn 16, Issue 1, 2017, Pages 20-28

  Permutt, Thomas ^a   Li, Feng ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

dropout; missing data; robust; trimmed mean

Indexed keywords

PLACEBO;

ADVERSE DRUG REACTION; ANALYTICAL ERROR; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; MEDICAL DOCUMENTATION; PAIN INTENSITY; PATIENT DROPOUT; SIMULATION; STATISTICAL ANALYSIS; STATISTICAL MODEL; METHODOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

DATA INTERPRETATION, STATISTICAL; HUMANS; MODELS, STATISTICAL; PATIENT DROPOUTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84994681062     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.1768     Document Type: Conference Paper

References (17)

1. National Research Council. The prevention and treatment of missing data in clinical trials. National Academies Press: Washington, 2010.
2. Shih WJ, Quan H. Testing for treatment differences with dropouts present in clinical trials–A composite approach. Statistics in Medicine 1997; 16:1225–1239.
3. Kenward MG. The handling of missing data in clinical trials. Clinical Investigation 2013; 3:241–250.
4. Tukey J. Memorandum reports 31-34. Statistical Research Group, Princeton University, 1946.
5. Huber PJ. Robust estimation of a location parameter. Annals of Mathematical Statistics 1964; 35:73–101.
6. Bickel PJ. On some robust estimates of location. Annals of Mathematical Statistics 1965; 36:847–858.
7. Stigler SM. The asymptotic distribution of the trimmed mean. Annals of Statistics 1973; 1:472–477.
8. Gould AL. A new approach to the analysis of clinical drug trials with withdrawals. Biometrics 1980; 36:721–727.
9. Brown MB. A test for the difference between two treatments in a continuous measure of outcome when there are dropouts. Controlled Clinical Trials 1992; 13:213–225.
10. Pincus T, Amara I, Koch GG. Continuous indices of Core Data Set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria. Arthritis & Rheumatism 2005; 52:1031–1036.
11. Farrar JT, Dworkin RH, Max MB. Use of the cumulative proportion of responders analysis graph to present pain data over a range of cut-off points: making clinical trial data more understandable. Journal of Pain and Symptom Management 2006; 31:369–377.
12. Permutt T, Buenconsejo J. Responder analysis in analgesic trials: you can have it both ways. Proceedings of the Joint Statistical Meetings: Minneapolis, 2005.
13. Permutt T. A taxonomy of estimands for regulatory clinical trials with discontinuations. Statistics in Medicine 2015: n/a–n/a. DOI: 10.1002/sim.6841.
14. Senn S, Stevens L, Chaturvedi N. Repeated measures in clinical trials: simple strategies for analysis using summary measures. Statistics in Medicine 2000; 19:861–877.
15. Bamia C, White IR, Kenward MG. Some consequences of assuming simple patterns for the treatment effect over time in a linear mixed model. Statistics in Medicine 2013; 32:2585–2594.
16. Mallinckrodt C, Roger J, Chuang-Stein C, Molenberghs G, O'Kelly M, Ratitch B, Janssens M, Bunouf P. Recent developments in the prevention and treatment of missing data. Therapeutic Innovation & Regulatory Science 2013; 48(1):369–382.
17. Leuchs A-K, Zinserling J, Brandt A, Wirtz D. Choosing appropriate estimands in clinical Trials. Therapeutic Innovation & Regulatory Science 2015; 49(4):584–592.